Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer.

Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olopade OI.

J Clin Oncol. 2009 Sep 20;27(27):4515-21. doi: 10.1200/JCO.2008.19.6873. Epub 2009 Aug 24.

2.

Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil.

Carvalho FM, Bacchi LM, Pincerato KM, Van de Rijn M, Bacchi CE.

BMC Womens Health. 2014 Aug 29;14:102. doi: 10.1186/1472-6874-14-102.

3.

Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.

Cherbal F, Gaceb H, Mehemmai C, Saiah I, Bakour R, Rouis AO, Boualga K, Benbrahim W, Mahfouf H.

Breast Dis. 2015;35(2):95-102. doi: 10.3233/BD-150398.

PMID:
25736840
4.

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC.

JAMA. 2006 Jun 7;295(21):2492-502.

PMID:
16757721
5.

Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study.

Dawood S, Hu R, Homes MD, Collins LC, Schnitt SJ, Connolly J, Colditz GA, Tamimi RM.

Breast Cancer Res Treat. 2011 Feb;126(1):185-92. doi: 10.1007/s10549-010-1113-7. Epub 2010 Aug 14.

6.

Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.

Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, Patel AH, Lacey JV Jr.

J Natl Cancer Inst. 2012 Jul 18;104(14):1094-101. doi: 10.1093/jnci/djs264. Epub 2012 Jul 5.

7.

Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.

Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA.

J Surg Res. 2007 Nov;143(1):109-18.

PMID:
17950079
8.

Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series.

McCormack VA, Joffe M, van den Berg E, Broeze N, Silva Idos S, Romieu I, Jacobson JS, Neugut AI, Schüz J, Cubasch H.

Breast Cancer Res. 2013;15(5):R84.

9.

Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.

O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC.

Clin Cancer Res. 2010 Dec 15;16(24):6100-10. doi: 10.1158/1078-0432.CCR-10-1533.

11.

Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.

Puig-Vives M, Sánchez MJ, Sánchez-Cantalejo J, Torrella-Ramos A, Martos C, Ardanaz E, Chirlaque MD, Perucha J, Díaz JM, Mateos A, Machón M, Marcos-Gragera R.

Gynecol Oncol. 2013 Sep;130(3):609-14. doi: 10.1016/j.ygyno.2013.05.039. Epub 2013 Jun 6.

PMID:
23747837
12.
13.

Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China.

Zhu X, Ying J, Wang F, Wang J, Yang H.

Breast Cancer Res Treat. 2014 Oct;147(3):551-5. doi: 10.1007/s10549-014-3136-y. Epub 2014 Sep 19.

PMID:
25234844
14.

Immunohistochemical profile and clinical-pathological variables in breast cancer.

Cintra JR, Teixeira MT, Diniz RW, Gonçalves Junior H, Florentino TM, Freitas GF, Oliveira LR, Neves MT, Pereira T, Guerra MR.

Rev Assoc Med Bras (1992). 2012 Mar-Apr;58(2):178-87. English, Portuguese.

15.

Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis.

Eng A, McCormack V, dos-Santos-Silva I.

PLoS Med. 2014 Sep 9;11(9):e1001720. doi: 10.1371/journal.pmed.1001720. eCollection 2014 Sep 9. Review.

16.

Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer.

Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, Brachtel EF, Schapira L, Come SE, Winer EP, Partridge AH.

Breast Cancer Res Treat. 2012 Feb;131(3):1061-6. doi: 10.1007/s10549-011-1872-9. Epub 2011 Nov 13.

PMID:
22080245
17.

Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study.

Bao PP, Shu XO, Gao YT, Zheng Y, Cai H, Deming SL, Ruan ZX, Su Y, Gu K, Lu W, Zheng W.

Am J Epidemiol. 2011 Sep 15;174(6):661-71. doi: 10.1093/aje/kwr145. Epub 2011 Jul 18.

18.

Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium.

Luyeye Mvila G, Batalansi D, Praet M, Marchal G, Laenen A, Christiaens MR, Brouckaert O, Ali-Risasi C, Neven P, Van Ongeval C.

Breast. 2015 Oct;24(5):642-8. doi: 10.1016/j.breast.2015.07.031. Epub 2015 Aug 14.

PMID:
26279132
19.

High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.

Nishimukai A, Yagi T, Yanai A, Miyagawa Y, Enomoto Y, Murase K, Imamura M, Takatsuka Y, Sakita I, Hatada T, Miyoshi Y.

Clin Breast Cancer. 2015 Jun;15(3):204-11. doi: 10.1016/j.clbc.2014.12.007. Epub 2014 Dec 24.

PMID:
25600243
20.

Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women.

Ma H, Lu Y, Marchbanks PA, Folger SG, Strom BL, McDonald JA, Simon MS, Weiss LK, Malone KE, Burkman RT, Sullivan-Halley J, Deapen DM, Press MF, Bernstein L.

Breast Cancer Res. 2013;15(5):R90.

Supplemental Content

Support Center